MRSA Drugs Market 2023: Share, Key Players, Latest Insights and Forecast to 2028

According to IMARC Group’s latest report, titled “MRSA Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the MRSA drugs market share. 

The global MRSA drugs market size reached US$ 3.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028. Methicillin-resistant Staphylococcus aureus (MRSA) represents an infection caused by antibiotic-resistant strains of staphylococcus aureus that commonly occurs in patients who receive intravenous tubing, undergo surgical procedures, or come in contact with each other skin-to-skin. The medicines are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection to kill or restrain it. The most common MRSA drugs consist of clindamycin, minocycline, trimethoprim-sulfamethoxazole, linezolid, or doxycycline. These medicines are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can appear in hospitals or from the community; hence the treatment can sometimes involve administering oral medications and intravenous (IV) remedies, depending on the stringency. Various drugs can be used to treat several conditions, including skin infections, bone disorders, bacteremia, and even zoonotic diseases in animals.

Download free sample brochure: https://www.imarcgroup.com/mrsa-drugs-market/requestsample

MRSA Drugs Market Trends:

The escalating prevalence of antibiotic resistant strains development among the masses, the increasing cases of hospital-acquired infections (HAIs) across the globe, and the growing geriatric population that is more sensitive to developing these infections are primarily driving the MRSA drugs market. Besides this, the rising awareness toward the various forms of bacterial infection, continuous product innovations, the high number of clinical trials, and the introduction of novel medicine variants are further augmenting the market growth. Moreover, the launch of several diagnostic tools, the increasing trial programs for the screening of antibiotic resistant strains of bacteria, and the extensive research and development (R&D) activities by the leading players are also catalyzing the global market. Apart from this, the elevating requirement for generic medications against presently available products, easy availability of antibiotics across online and offline organized platforms, the emerging trend of urbanization, and the inflating medical expenditure

MRSA Drugs Market 2023-2028 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the MRSA drugs market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

• AbbVie Inc.
• Basilea Pharmaceutica Ltd
• Crystal Genomics Inc.
• Cumberland Pharmaceuticals Inc.
• Melinta Therapeutics Inc
• Paratek Pharmaceuticals, Inc.
• Pfizer Inc

Key Market Segmentation:

The report has segmented the global MRSA drugs market based on type, drug class, disease indication, route of administration, distribution channel and region.

Breakup by MRSA Type:

• Hospital-Acquired (HA-MRSA)
• Community-Acquired (CA-MRSA)

Breakup by Drug Class:

• Lipopeptides
• Oxazolidinones
• Cephalosporin
• Tetracycline
• Folate Antagonist
• Others

Breakup by Disease Indication:

• Skin Infections
• Bone and Joint Infections
• Bacteremia
• Animal Infections

Breakup by Route of Administration:

• Oral Administration
• Parenteral Administration

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Breakup by Region:

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, Others)
• Middle East and Africa ( Turkey, Saudi Arabia, Iran, United Arab Emirates, Others)

Ask Analyst for 10% free customized report: https://www.imarcgroup.com/mrsa-drugs-market

Key Highlights of the Report:

• Market Performance (2017-2022)
  • Market Outlook (2023-2028)
  • Market Trends
  • Market Drivers and Success Factors
  • Impact of COVID-19
  • Value Chain Analysis
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:
IMARC Group
134 N 4th St Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe Africa: +44-753-713-2163 | Asia: +91-120-433-0800

Article source: https://article-realm.com/article/Finance/39259-MRSA-Drugs-Market-2023-Share-Key-Players-Latest-Insights-and-Forecast-to-2028.html